Effect of lopinavir/ritonavir treatment on COVID-2019 transmissibility:
A possible option to reduce isolation time
Abstract
Background: Owing to the coronavirus disease 2019 (COVID-19) pandemic,
there is a shortage of hospital wards to accommodate the increasing
number of patients, especially in intensive care units. Healthcare
systems are collapsing in many countries. Therefore, it is necessary to
reduce isolation time. Methods: We examined the effect of
lopinavir/ritonavir administration in patients with SARS-CoV-2. To
assess the viral load, duration and clearance of viable virus; cell
culture and RT-PCR were performed in parallel. Results: No viable
SARS-CoV-2 could be detected after administration of lopinavir/ritonavir
with median time of viable viral clearance being one day after
administration. The mean viral load in both upper and lower respiratory
tract samples of lopinavir/ritonavir administered group was
significantly lower than the group who were not treated with any
antiviral agent. The duration of viable viral shedding was shorter in
patients with lopinavir/ritonavir treatment compared with those without
treatment. Conclusion: This study suggests that lopinavir/ritonavir
treatment offers a possible method to reduce isolation time of patients
infected with the SARS-CoV-2.